Category Archives: Immunology of Infectious Disease

No account yet? Register

industry & policy

Adamis Pharmaceuticals Announces License to Commercialize Tempol, a Novel Investigational Anti-inflammatory and Antioxidant Drug for the Treatment of Respiratory Diseases Including COVID-19

Adamis Pharmaceuticals Corporation announced a license to commercialize Tempol, a novel patented investigational drug for the treatment of COVID-19. The license includes the worldwide use of Tempol for the treatment of all respiratory diseases including asthma, respiratory syncytial virus, influenza and COVID-19.

[Adamis Pharmaceuticals]

Press Release

No account yet? Register

Systemically Comparing Host Immunity between Survived and Deceased COVID-19 Patients

Scientists summarized the characteristics of cellular immune responses in a total of 157 COVID-19 patients enrolled in Tongji Hospital between February and March 2020 and compare the properties between 95 survived and 62 deceased patients with different onset time.

[Cellular & Molecular Immunology]

No account yet? Register

industry & policy

Pluristem Announces Activation of Clinical Sites and Commencement of Patient Enrollment in US FDA Phase II COVID-19 ARDS Trial

Pluristem Therapeutics, Inc. announced the activation of clinical sites and initiation of enrollment in its Phase II US FDA study of PLX cells for the treatment of severe COVID-19 complicated by Acute Respiratory Distress Syndrome (ARDS).

[Pluristem Therapeutics, Inc. ]

Graphical Abstract

No account yet? Register

Optimization of Primer Sets and Detection Protocols for SARS-CoV-2 of Coronavirus Disease 2019 (COVID-19) Using PCR and Real-Time PCR

Scientists provide three-step guidelines for the design and optimization of specific primer sets. The three steps include the selection of primer sets for target genes in the genome of SARS-CoV-2, the in silico validation of primer and amplicon sequences, and the optimization of PCR conditions for specific hybridization between the primers and target genes, and the elimination of spurious primer dimers.

[Experimental and Molecular Medicine]

No account yet? Register

industry & policy

UCLA Receives Nearly $14 Million from NIH to Investigate Gene Therapy to Combat HIV

University of California, Lost Angeles (UCLA) researchers and colleagues have received a $13.65 million grant from the National Institutes of Health to investigate and further develop an immunotherapy known as CAR T, which uses genetically modified stem cells to target and destroy HIV.

[Univesity of California, Los Angeles]

Graphical Abstract

No account yet? Register

Potential Antiviral Options against SARS-CoV-2 Infection

Investigators developed a neutralization assay using SARS-CoV-2 strain and Vero-E6 cells. They identified the most potent sera from recovered patients for the treatment of SARS-CoV-2-infected patients. They also screened 136 safe-in-man broad-spectrum antivirals against the SARS-CoV-2 infection in Vero-E6 cells and identified nelfinavir, salinomycin, amodiaquine, obatoclax, emetine and homoharringtonine.

[Viruses]

No account yet? Register

HIV-1-Associated Left Ventricular Cardiac Dysfunction in Humanized Mice

Longitudinal echocardiography was used to assess whether NOD.Cg-Prkdc^scidIl2rgt^m1Wjl/SzJ mice reconstituted with human hematopoietic stem cells and infected with HIV-1ADA could recapitulate the salient features of HIV-1 infection.

[Scientific Reports]

Abstract

No account yet? Register

Abstract Graphical Abstract

CBASS Immunity Uses CARF-Related Effectors to Sense 3′–5′- and 2′–5′-Linked Cyclic Oligonucleotide Signals and Protect Bacteria from Phage Infection

Investigators discovered Enterobacter cloacae CD-NTase-associated protein 4 (Cap4) as a founding member of a diverse family of >2,000 bacterial receptors that responded to CD-NTase signals. Structures of Cap4 revealed a promiscuous DNA endonuclease domain activated through ligand-induced oligomerization.

[Cell]

No account yet? Register

review

Considering How Biological Sex Impacts Immune Responses and COVID-19 Outcomes

The authors discuss available sex-disaggregated epidemiological data from the COVID-19 pandemic, introduce sex-differential features of immunity and highlight potential sex differences underlying COVID-19 severity.

[Nature Reviews Immunology]

No account yet? Register

Abstract Graphical Abstract

The Intermucosal Connection between the Mouth and Gut in Commensal Pathobiont-Driven Colitis

Investigators report that periodontal inflammation exacerbates gut inflammation in vivo. Periodontitis led to expansion of oral pathobionts, including Klebsiella and Enterobacter species, in the oral cavity.

[Cell]